Krystal Biotech, Inc.
KRYS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $98 | $96 | $88 | $91 |
| % Growth | 1.8% | 8.9% | -3.2% | – |
| Cost of Goods Sold | $6 | $7 | $5 | $5 |
| Gross Profit | $92 | $89 | $83 | $86 |
| % Margin | 94.2% | 92.5% | 94.3% | 94.6% |
| R&D Expenses | $13 | $14 | $14 | $14 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $38 | $35 | $33 | $31 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $51 | $50 | $47 | $45 |
| Operating Income | $41 | $39 | $36 | $41 |
| % Margin | 42.3% | 40.9% | 41% | 45.4% |
| Other Income/Exp. Net | $7 | $7 | $7 | $7 |
| Pre-Tax Income | $48 | $47 | $44 | $49 |
| Tax Expense | -$31 | $8 | $8 | $3 |
| Net Income | $79 | $38 | $36 | $45 |
| % Margin | 81.2% | 39.9% | 40.5% | 49.9% |
| EPS | 2.741 | 1.33 | 1.24 | 1.58 |
| % Growth | 106.1% | 7.3% | -21.5% | – |
| EPS Diluted | 2.66 | 1.29 | 1.2 | 1.52 |
| Weighted Avg Shares Out | 29 | 29 | 29 | 29 |
| Weighted Avg Shares Out Dil | 30 | 30 | 30 | 30 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $7 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | $2 | $2 |
| EBITDA | $50 | $41 | $38 | $43 |
| % Margin | 50.7% | 42.5% | 42.9% | 47.1% |